Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

LAW May 6, 2026

CS Disco Q1 2026 Earnings Call - AI Platform Launch Drives Revenue Beat and Margin Expansion

CS Disco delivered a strong Q1 2026, beating revenue and adjusted EBITDA guidance as the launch of the all-in-one DISCO Platform and deepening AI adoption accelerated growth. Total revenue rose 14% ye...

  • Total revenue grew 14% year-over-year to $41.9 million, beating the high end of guidance.
  • Software revenue increased 12% to $34.7 million, marking the fourth consecutive quarter of accelerating growth.
  • Adjusted EBITDA improved 600 basis points to a negative $3.5 million, outperforming the high end of guidance.
  • +7 more takeaways
GOLF May 6, 2026

Acushnet Company Q1 2026 Earnings Call - Accelerated GTS Driver Launch and Tariff Uncertainty Offset by Strong Equipment Growth

Acushnet delivered a solid first quarter, with net sales rising 5% constant currency to $753 million and adjusted EBITDA up 4% to $145 million. The results were driven by strong momentum in Titleist g...

  • Worldwide net sales increased 5% on a constant currency basis to $753 million in Q1 2026.
  • Adjusted EBITDA rose 4% year-over-year to $145 million, up $6 million from Q1 2025.
  • Titleist golf equipment sales grew 7%, supported by strong demand for balls and clubs.
  • +7 more takeaways
RPRX May 6, 2026

Royalty Pharma Q1 2026 Earnings Call - Double-Digit Growth and R&D Co-Funding Surge

Royalty Pharma delivered a robust first quarter, growing portfolio receipts by 10% and recurring royalty receipts by 13%, driven by a diversified portfolio and strong clinical catalysts. Management ra...

  • Royalty Pharma reported 10% growth in portfolio receipts and 13% growth in recurring royalty receipts for Q1 2026, demonstrating the resilience of its diversified portfolio.
  • Management raised full-year 2026 guidance for portfolio receipts to $3.325 billion–$3.45 billion, up from the previous range of $3.275 billion–$3.425 billion.
  • The company announced $1.25 billion in new transactions, including a $250 million upfront investment for a royalty on Ziihera, a HER2-targeted cancer therapy with blockbuster potential in gastric cancer.
  • +9 more takeaways
SEDG May 6, 2026

SolarEdge Q1 2026 Earnings Call - Transitioning to Offensive Growth with Near-Break-Even Results and Strategic Shifts

SolarEdge delivered a pivotal Q1 2026 report that underscores a decisive shift from defensive cost-cutting to offensive growth, marked by 46% year-over-year revenue expansion and a clear path to near-...

  • Q1 revenue surged 46% year-over-year to $310 million, marking the fifth consecutive quarter of growth without significant revenue pull-forward.
  • Management guided for Q2 revenue between $325-$355 million, with a midpoint EBIT loss of approximately $3.5 million, signaling a near-break-even milestone.
  • Non-GAAP gross margin expanded slightly to 23.5%, driven by a favorable product mix and lower seasonal warranty costs, while operating expenses came in well below guidance.
  • +7 more takeaways
CVGI May 6, 2026

CVG Q1 2026 Earnings Call - Electrical Systems Momentum Offsets Class 8 Weakness

CVG delivered a mixed first quarter, with revenue growth and margin expansion in its Global Electrical Systems and Global Seating segments partially offset by a sharp pullback in Trim Systems. The com...

  • Revenue reached $171.5 million, up slightly from $169.8 million in Q1 2025, driven by strength in Global Electrical Systems and Global Seating.
  • Global Electrical Systems revenue surged 14% year-over-year to $57.4 million, fueled by new business wins and the production ramp for the Zoox autonomous vehicle program.
  • Global Seating revenue grew 1.5% to $74.5 million, supported by higher international volumes and a 20% increase in aftermarket orders.
  • +7 more takeaways
MDGL May 6, 2026

Madrigal Pharmaceuticals Q1 2026 Earnings Call - Rezdiffra Hits $1.1B Run Rate as MASH Market Expands 50%

Madrigal Pharmaceuticals delivered a commanding first quarter, with Rezdiffra net sales surging 127% year-over-year to $311 million and trailing twelve-month revenue crossing the $1.1 billion mark. Th...

  • 1. Rezdiffra net sales surged 127% year-over-year to $311 million in Q1 2026, with trailing twelve-month revenue exceeding $1.1 billion, confirming blockbuster status.
  • 2. The U.S. addressable MASH market grew nearly 50% in two years, expanding from 315,000 to 460,000 diagnosed patients, driven by increased awareness and specialist involvement.
  • 3. Active patients on Rezdiffra more than doubled year-over-year, reaching over 42,250, with management noting strong momentum carrying into Q2 2026.
  • +7 more takeaways
TX May 6, 2026

Ternium Q1 2026 Earnings Call - Mexican Steel Demand Recovery and USMCA Uncertainty

Ternium reported a 21% sequential increase in adjusted EBITDA for Q1 2026, driven by margin improvements and favorable foreign exchange movements, despite rising raw material costs. The company is nav...

  • Adjusted EBITDA rose 21% sequentially in Q1 2026, reflecting margin expansion and foreign exchange gains, though raw material and logistics costs are rising.
  • Mexican steel demand is expected to recover in Q2 2026, supported by government policies prioritizing domestic steel in public procurement and a shift from destocking to normalization.
  • The Pesquería project in Mexico is ramping up ahead of schedule, with the cold rolling mill and galvanizing line expected to reach full capacity by October, enhancing vertical integration.
  • +9 more takeaways
CC May 6, 2026

Chemours {Q1} {2026} Earnings Call - Quota Discipline and Pricing Power Drive Record TSS EBITDA Amid APM Recovery

Chemours delivered a first quarter that defied expectations, powered by record performance in its Thermal & Specialized Solutions (TSS) segment and disciplined pricing execution across Titanium Techno...

  • TSS delivered a record first quarter with net sales up 22% year-over-year, driven by higher pricing, stronger volume growth, and favorable product mix in Freon and Opteon refrigerants.
  • TT adjusted EBITDA exceeded expectations despite lower global volumes, thanks to disciplined global pricing execution and strong cost management, with a new long-term chlorine supply contract signed with Olin for the DeLisle site.
  • APM reported a $25 million adjusted EBITDA headwind due to the Washington Works outage and prior Capstone line closure, but order velocity in high-value semiconductor and data center markets has reached multi-year highs.
  • +7 more takeaways
BLMN May 6, 2026

Bloomin' Brands Q1 2026 Earnings Call - Guest Scores Climb as Turnaround Strategy Takes Hold

Bloomin' Brands reported a solid Q1 2026, with U.S. comparable restaurant sales rising 90 basis points despite a 180 basis point traffic decline heavily impacted by severe winter weather. The company’...

  • U.S. comparable restaurant sales rose 90 basis points in Q1 2026, driven by a 270 basis point increase in average check, despite a 180 basis point traffic decline heavily offset by 240 basis points of severe winter weather impact.
  • Outback Steakhouse’s guest metric scores improved for the third consecutive quarter, with brand trust up 4 points and significant gains in service, value, atmosphere, food quality, and intent to return.
  • Management is executing a four-platform turnaround strategy focused on remarkable dine-in experience, brand relevancy, culture of ownership, and restaurant investment, with a new service model reducing server stations from six to four tables launching in April.
  • +7 more takeaways
UBER May 6, 2026

Uber Q1 2026 Earnings Call - Insurance Savings Fuel Mobility Acceleration and Profitable Expansion

Uber reported a strong start to 2026, with gross bookings up 21% year-over-year and non-GAAP EPS surging 44%. The company delivered top-line and profitability at or above the high end of guidance, dri...

  • Gross bookings grew 21% year-over-year, with mobility accelerating to 20% growth and record margins, while delivery expanded 23% driven by grocery and retail.
  • Non-GAAP EPS increased 44% year-over-year, more than twice the pace of bookings growth, reflecting significant operating leverage and disciplined cost management.
  • Insurance cost savings in U.S. mobility markets, particularly Los Angeles and San Francisco, are materializing, leading to lower consumer prices, increased trip elasticity, and accelerating growth.
  • +9 more takeaways